Literature DB >> 3158508

Ciclopirox olamine 1% cream. A preliminary review of its antimicrobial activity and therapeutic use.

S G Jue, G W Dawson, R N Brogden.   

Abstract

Ciclopirox olamine is a substituted pyridone antimycotic, unrelated to the imidazole derivatives, with activity against a broad spectrum of dermatophytes, yeasts, actinomycetes, molds, other fungi, and a variety of Gram-positive and Gram-negative bacteria. The efficacy of ciclopirox olamine cream has been demonstrated in open and placebo-controlled studies in patients with superficial dermatophyte or yeast infections, and in double-blind comparative trials in patients with dermatomycoses, topical ciclopirox olamine was comparable to or better than clotrimazole in efficacy and caused a similar number of side effects. Ciclopirox olamine penetrates through fingernails and in preliminary studies has been successfully used in onychomycoses. However, further studies are needed to establish the role of ciclopirox in the treatment of onychomycoses and dermatomycoses relative to that of the more recently introduced antigungal agents.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3158508     DOI: 10.2165/00003495-198529040-00002

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  13 in total

1.  Contribution to the methodology of testing topical antimycotic agents in guinea pig dermatophytosis.

Authors:  W Dittmar
Journal:  Mykosen       Date:  1975-08

2.  Amino acid transport in yeast and effects of nystatin.

Authors:  E STACHIEWICZ; J H QUASTEL
Journal:  Can J Biochem Physiol       Date:  1963-02

3.  Studies on uptake of 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone ethanolamine salt (Hoe 296) by Candida albicans.

Authors:  K Sakurai; T Sakaguchi; H Yamaguchi; K Iwata
Journal:  Chemotherapy       Date:  1978       Impact factor: 2.544

4.  Mode of action of 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone ethanolamine salt (Hoe 296).

Authors:  K Sakurai; T Sakaguchi; H Yamaguchi; K Iwata
Journal:  Chemotherapy       Date:  1978       Impact factor: 2.544

5.  [A comparative double blind trial with vaginal creams of cyclopyroxolamine and miconazole in vulvovaginal candidosis (author's transl)].

Authors:  M Wajnberg; A Wajnberg
Journal:  Mykosen       Date:  1981-12

6.  [Pharmacokinetics and biotransformation of the antimycotic drug ciclopiroxolamine in animals and man after topical and systemic administration].

Authors:  H M Kellner; C Arnold; O E Christ; H G Eckert; J Herok; I Hornke; W Rupp
Journal:  Arzneimittelforschung       Date:  1981

7.  [Studies on the pharmacology and toxicology of ciclopiroxolamine (author's transl)].

Authors:  H G Alpermann; E Schütz
Journal:  Arzneimittelforschung       Date:  1981

8.  [Clinical results with the antimycotic agent ciclopiroxolamine (author's transl)].

Authors:  W Adam; H G Peil; C Savopoulos; O Vanderbeke
Journal:  Arzneimittelforschung       Date:  1981

9.  [Comparative double-blind study on ciclopiroxolamine cream and placebo cream in dermatophytoses (author's transl)].

Authors:  T Fredriksson; C Savopoulos
Journal:  Arzneimittelforschung       Date:  1981

10.  [On the local efficacy of ciclopiroxolamine in onychomycoses (author's transl)].

Authors:  S A Qadripur; G Horn; T Höhler
Journal:  Arzneimittelforschung       Date:  1981
View more
  23 in total

1.  In vitro antifungal efficacy of ciclopirox olamine alone and associated with zinc pyrithione compared to ketoconazole against Malassezia globosa and Malassezia restricta reference strains.

Authors:  Christine Roques; Sabine Brousse; Cédric Panizzutti
Journal:  Mycopathologia       Date:  2006-12       Impact factor: 2.574

2.  Identification of Off-Patent Drugs That Show Synergism with Amphotericin B or That Present Antifungal Action against Cryptococcus neoformans and Candida spp.

Authors:  Suélen Andreia Rossi; Haroldo Cesar de Oliveira; Daniel Agreda-Mellon; José Lucio; Maria José Soares Mendes-Giannini; Jesús Pablo García-Cambero; Oscar Zaragoza
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

Review 3.  An overview of topical antifungal therapy in dermatomycoses. A North American perspective.

Authors:  A K Gupta; T R Einarson; R C Summerbell; N H Shear
Journal:  Drugs       Date:  1998-05       Impact factor: 9.546

Review 4.  Repositioning the Old Fungicide Ciclopirox for New Medical Uses.

Authors:  Tao Shen; Shile Huang
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

Review 5.  Pharmacokinetics of antifungal agents in onychomycoses.

Authors:  D Debruyne; A Coquerel
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

6.  Observations on effects of ciclopirox olamine on dermatophytosis.

Authors:  Y C Zheng; T H Xu; S M Wang; J M Xie; Z R Zhu; Z J Yang
Journal:  J Tongji Med Univ       Date:  1987

Review 7.  Pharmacoeconomic analysis of topical treatments for tinea infections.

Authors:  N H Shear; T R Einarson; S R Arikian; J J Doyle
Journal:  Pharmacoeconomics       Date:  1995-03       Impact factor: 4.981

8.  Ciclopirox protects mitochondria from hydrogen peroxide toxicity.

Authors:  Sun J Lee; Youngnam Jin; Hye Young Yoon; Byung-Ok Choi; Hyoung Chun Kim; Yu-Kyoung Oh; Hee-Sun Kim; Won-Ki Kim
Journal:  Br J Pharmacol       Date:  2005-06       Impact factor: 8.739

9.  The antitumor activity of the fungicide ciclopirox.

Authors:  Hongyu Zhou; Tao Shen; Yan Luo; Lei Liu; Wenxing Chen; Baoshan Xu; Xiuzhen Han; Jia Pang; Chantal A Rivera; Shile Huang
Journal:  Int J Cancer       Date:  2010-11-15       Impact factor: 7.396

Review 10.  Treatment and prophylaxis of tinea infections.

Authors:  G E Piérard; J E Arrese; C Piérard-Franchimont
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.